iBio, Inc. has received a notice from the Nasdaq Stock Market regarding its compliance with listing requirements. The company was informed that its common stock did not maintain the minimum closing bid price of $1.00 per share for 30 consecutive business days, from October 8 to November 18, 2026. This notice is significant as it puts the company at risk of delisting from the exchange, although it currently continues to trade under the symbol 'IBIO.'
The situation is critical for iBio, which operates in the pharmaceutical preparations industry. The company now has a compliance period of 180 days, until May 18, 2027, to regain compliance with Nasdaq's listing standards. If the stock price reaches or exceeds the $1.00 requirement for at least 10 consecutive business days during this period, Nasdaq will consider the company in compliance.
Background
iBio, Inc. is a Delaware-based company primarily engaged in the pharmaceutical preparations sector, classified under the SIC code 2834. The company trades on the Nasdaq exchange under the ticker symbol 'IBIO.' Recent filings indicate that iBio has been active in providing updates on its financial performance and compliance status.
What the Filing Says
According to the filing dated November 20, 2026, "the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC... that for the preceding 30 consecutive business days... the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share." The notice does not immediately affect the trading of the company's stock.
Impact
This notice may affect investors and shareholders of iBio, as it highlights the company's struggle to maintain its listing on a major exchange. The compliance period allows the company time to implement strategies to boost its stock price, which may include potential measures such as a reverse stock split.
What's Next
The company intends to monitor its stock price closely and will consider options to regain compliance with Nasdaq's listing requirements. This includes potentially executing a reverse stock split if necessary. Further updates are expected as the compliance period progresses.
Read Next
Alps Group Regains Compliance with Nasdaq Listing Standards
Ainos, Inc. Receives Nasdaq Delisting Notice Over Equity
Compass Therapeutics Receives Nasdaq Deficiency Notice
60 Degrees Pharmaceuticals Faces Nasdaq Delisting Risk
Biofrontera Inc. Faces Nasdaq Delisting Due to Low Stock Price
Senti Biosciences dismisses KPMG, appoints new auditor KNAV










